During the past week, Depomed (DEPO) announced two significant business development updates. On March 15th, Depomed granted non-exclusive rights for its proprietary extended-release metformin patents, this time, to Boehringer Ingelheim. On March 16th, Depomed announced that they and Abbott (ABT) have reached an agreement over Gralise.
Moving Forward From Abbott
The details of the agreement between Abbott and Depomed, were released in an SEC filing, after the market close. The filing provides for, the immediate termination of the previous agreement, a $40 million dollar payment to Depomed, and a transition plan for Gralise back to Depomed.
Many industry commentators have been puzzled by the negotiations between Abbott and Depomed. Some believe that Abbott's lack of interest is due in-part to Gralise's lack of "blockbuster" potential. Adam Feuerestien, a biotech columnist for Street.com, was puzzled about "how
Complete Story »
Carrie Underwood Rosario Dawson Tricia Helfer Elena Lyons Brooke Burns
No comments:
Post a Comment